SCHEMBL2437834

SCHEMBL2437834

FC(F)(F)c1nc2ccccc2nc1-c1cc2nc(Cl)cc(Cl)n2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.39
PDE10A Q9Y233 1/20 0.36
MAPT P10636 6/20 0.35
NPSR1 Q6W5P4 4/20 0.35
POLB P06746 3/20 0.35
ALDH1A1 P00352 3/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2C19 P33261 2/20 0.35
HTT P42858 2/20 0.35
CYP2C9 P11712 1/20 0.35
ATM Q13315 1/20 0.35
KDM4E B2RXH2 7/20 0.35
L3MBTL1 Q9Y468 3/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
HPGD P15428 2/20 0.34
NPC1 O15118 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2437251 0.81 PDE10A (0.41) TP53PDE10AMAPTALDH1A1CYP2C19
SCHEMBL2442272 0.79 TP53 (0.40) TP53PDE10AMAPTALDH1A1KDM4E
SCHEMBL2443303 0.78 PDE10A (0.36) TP53PDE10AMAPTNPSR1ALDH1A1
SCHEMBL2431482 0.78 PDE10A (0.46) PDE10A
SCHEMBL2437615 0.76 PDE10A (0.46) PDE10AMAPTALDH1A1CYP2C19HTT
SCHEMBL2438684 0.75 KDM4E (0.42) TP53PDE10ACYP1A2KDM4E
SCHEMBL13263646 0.73 NPC1 (0.53) TP53PDE10AMAPTALDH1A1CYP2C19
SCHEMBL2438425 0.71 PDE10A (0.45) TP53PDE10AMAPTALDH1A1KDM4E
SCHEMBL2440809 0.71 DPP4 (0.36) PDE10AMAPTALDH1A1CYP2C19HTT
SCHEMBL2443008 0.70 KDM4E (0.38) TP53PDE10AMAPTALDH1A1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2539342-B1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2015-04-15 EP disclosed
US-8969376-B2 Pyrazolopyrimidine compounds and their use as PDE10 inhibitors MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-03-03 US disclosed
EP-2539342-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS Mitsubishi Tanabe Pharma Corporation (JP) 2013-01-02 EP disclosed
US-20120309754-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-12-06 US disclosed
WO-2011105628-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309754-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS PDE3B, PDE3A, PDE5A TP53 4616/4885PDE10A 5/4885MAPT 4404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.